GLP-1 Blood Pressure Effects: How Much They Lower BP — and When It Can Drop Too Low

GLP-1 blood pressure effects usually point down, not up. In obesity trials, semaglutide (Wegovy) lowered top-number blood pressure by about 5 mmHg, and tirzepatide (Zepbound) lowered it by roughly 7 to 11 mmHg on 24-hour monitoring — while nudging heart rate up a few beats. True low-blood-pressure episodes are uncommon, but two things raise the odds: dehydration and taking a blood pressure medicine at the same time.

If you’re here because your reading looked lower than usual, you felt dizzy standing up, or you take a blood pressure pill and just started a GLP-1 — take a breath. This question usually gets answered in pieces. Here’s the whole usable picture in one place: the real numbers for the main options, straight from the FDA labels and the actual trials, plus a simple way to tell an expected trend from a reading or symptom that deserves a call.

The 30-second version

Terminology: We use “GLP-1” the way most people search it. Technically, tirzepatide (Zepbound, Mounjaro) is a dual GIP/GLP-1 receptor agonist — it acts on two gut-hormone targets, not one. We’ll flag where that matters.

Already seeing lower numbers? Jump to the free 7-day blood pressure log →

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The right GLP-1 provider isn’t the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget.

What are the main GLP-1 blood pressure effects?

GLP-1 medicines usually lower systolic (top-number) blood pressure by a few points on average in weight-loss trials, and much of that drop appears to come from weight loss. That average change is a different thing from symptomatic low blood pressure — a reading low enough to cause dizziness or fainting — which was uncommon in the FDA trials but matters a lot when it happens.

Here’s the idea that clears up most of the confusion. There are three different things people mix together when they ask about GLP-1s and blood pressure.

1. The average trial effect — what happened to a whole group of people in a study. This is where the “−5 mmHg” type numbers come from.
2. Your personal change — what your own readings actually do. This can be more, less, or nothing at all.
3. A low-blood-pressure problem — an actual episode of pressure dropping too low, with symptoms like dizziness or fainting.

A GLP-1 can lower the group average (thing 1), while your own pressure barely moves (thing 2), and while a small number of people have a genuine low-BP episode (thing 3). All three can be true at once. When a headline says “GLP-1s lower blood pressure” and a forum post describes a sudden drop, they may be describing different things — and the forum post, on its own, isn’t proof the medicine caused it.

How much do semaglutide, tirzepatide, and Foundayo lower blood pressure?

Semaglutide (Wegovy) lowered top-number blood pressure by roughly 5 mmHg versus placebo across pooled obesity trials. Tirzepatide (Zepbound) lowered 24-hour blood pressure by 7.4 to 10.6 mmHg across its doses in a separate study. The oral pill Foundayo (orforglipron) lowered it about 5.7 points from where people started. These came from different trials with different people, so they aren’t a head-to-head “which one wins.”

This is our core original asset — the real, sourced numbers pulled together in one place, so you don’t have to open five journal tabs to find them.

Blood pressure change in the trials (FDA-approved products)

Here’s the honest catch. The medicines here can push two numbers in opposite directions: blood pressure tends to drift down, but resting heart rate drifts up a few beats. For the injectables, the FDA labels put the average bump at 1 to 4 beats per minute ¹ ². The oral pill Foundayo runs a bit higher — about 4 to 5 beats per minute on average ⁷. And “lower” isn’t automatically “better” — a lower reading that comes with symptoms is the thing to pay attention to.

For most people that heart-rate bump is small, and it didn’t cancel out the heart benefit where it’s been studied. In the SELECT trial specifically, Wegovy lowered the risk of major heart events in adults with established heart disease and overweight or obesity — pulse bump included ³. That result is about Wegovy in that group; it doesn’t automatically transfer to every GLP-1 or every person.

Does a GLP-1 lower the bottom number too?

It can, by less. In the tirzepatide 24-hour study, the bottom (diastolic) number fell about 2 to 3 mmHg at the 5 mg and 10 mg doses, with a smaller change at 15 mg that may have been chance. Foundayo lowered the bottom number about 2.4 points versus 1.4 on placebo — a real-looking change, but one the trial didn’t lock in as a formal result.

Most trials put the spotlight on the top number, because that’s the one most tied to heart risk. The bottom number tends to move less. If yours barely changes while your top number drops, that’s a normal pattern, not a red flag ⁵ ⁷.

How quickly can blood pressure change after starting or increasing a GLP-1?

The trials show blood pressure changing over months, not a set number of days — the results were measured at 36, 68, and 72 weeks. In one 72-week tirzepatide analysis, the average decline was fastest in the first six months and then leveled off. An early change right after a dose increase, or during vomiting or diarrhea, may be about fluid loss rather than a steady BP effect.

Don’t expect a dramatic drop in week one, and don’t panic over a single early reading either. The useful move in the first weeks is to set a baseline, measure again after each dose increase, and keep an eye on your fluids. If a low reading shows up right when you’re nauseated or not eating and drinking much, that’s a clue it may be dehydration — which is fixable — rather than the medicine settling your pressure ⁵.

Why do GLP-1s lower blood pressure?

Most of the drop seems to come from weight loss. In the semaglutide and tirzepatide analyses, researchers estimated that the large majority of the blood pressure change tracked with weight loss. Other effects on the blood vessels, kidneys, and nervous system may add a little, but scientists describe those as proposed, not settled.

When you lose a meaningful amount of weight, your heart doesn’t have to work as hard, and several drivers of high blood pressure ease up. That’s the big lever, and it’s what the numbers point to ⁴.

Researchers also float a few possible weight-independent effects — the medicine helping the body shed sodium, relaxing blood vessels a little, or calming an overactive “fight or flight” nervous system. These are reasonable theories, and the studies use careful words like “may” and “proposed.” We’ll do the same. What we won’t do is tell you a precise slice of the benefit is a “direct drug effect.” These are estimates of an average pattern, not a measurement of what happened inside any one person.

Can a GLP-1 make your blood pressure drop too low?

Yes — it’s uncommon but real. FDA labels report low-blood-pressure reactions in 1.3% of Wegovy users versus 0.4% on placebo, and 1.6% of Zepbound users versus 0.1% on placebo. Some of these episodes happened alongside vomiting, diarrhea, or dehydration, and both labels flag people who also take blood pressure medicine.

Wegovy and Zepbound: low-BP and heart-rate signals from the FDA labels

• •“Low blood pressure” here is a cluster, not one dramatic event. The labels group low BP, orthostatic hypotension (a drop when you stand), and simply “blood pressure decreased.”
• •Dehydration is the sneaky driver. Vomiting, diarrhea, or just not eating and drinking much — common in the first weeks or after a dose bump — can pull your fluid down and drop your pressure. If you can’t keep fluids down, that’s a call-your-clinician situation, not a wait-and-see one ¹ ².
• •Who was in these trials matters. In the pooled safety groups, about 42% of Wegovy participants and 41% of Zepbound participants already had high blood pressure at the start ¹ ². The tirzepatide 24-hour study only enrolled people with pressure under 140/90, and about a third were already on a blood pressure medicine ⁵.

Can you take a GLP-1 with blood pressure medicine?

Yes — they’re often used together, and concomitant use wasn’t flagged as an off-limits combination in the trials. But the FDA labels show low blood pressure was more common in people also taking blood pressure medicine, so it’s worth closer watching. Do not stop or lower a blood pressure medicine on your own — bring readings to the clinician who manages it.

This is the scenario that trips people up, so let’s be clear. Weight loss and the medicine can lower your pressure together, and adding a full-strength blood pressure pill on top can occasionally be too much — that’s where some people’s dizziness comes from.

In the semaglutide trials, people on the medicine were more likely to have their blood pressure treatment stepped down than people on placebo ⁴. That’s an encouraging sign — it can mean the weight loss is doing real work. But read the fine print: those changes happened inside medical care, with monitoring — not because someone decided on their own to skip a pill. Stopping some blood pressure medicines suddenly can be risky, and the safe adjustment depends on which one you take.

Is your dizziness from low blood pressure, dehydration, or something else?

Dizziness is a symptom, not a diagnosis. What causes it depends on the timing, whether it follows standing up, your reading during the symptom, recent vomiting or diarrhea, your fluid intake, your pulse, and your other medicines. A quick log of those details is what lets a clinician tell the difference.

Notice that “dizzy when you stand up” gets its own line. That pattern — feeling it specifically on standing, sometimes with your vision going dark for a second — is worth naming to your clinician, because it can point them toward a posture-, fluid-, or pressure-related cause.

Can a GLP-1 raise your blood pressure — or just your heart rate?

On average, the blood pressure signal in the obesity trials pointed down, not up — but any one person’s readings can bounce or rise and should be judged on their own pattern. Heart rate is a separate measurement: the Wegovy and Zepbound labels report small average increases in resting pulse even while blood pressure fell.

Two things people constantly confuse: blood pressure (the force in your arteries) and heart rate (how fast your heart beats). A GLP-1 tends to lower the first and slightly raise the second. That’s why you can see a “normal” blood pressure and a faster pulse at the same time and think something’s wrong — often that’s just the expected pattern.

On the pulse, averages hide the range. Wegovy’s label notes that 26% of people had a maximum jump of 20 beats per minute or more at some visit, versus 16% on placebo ¹. So a temporary faster reading isn’t unusual. Here’s the part to get right, because the labels differ: Wegovy’s label says to monitor your heart rate and to stop Wegovy if you have a sustained increase in resting heart rate ¹. The current Zepbound label reports a smaller average rise (1 to 3 bpm) but does not include that same stop instruction ². Foundayo’s average rise runs higher again (about 4 to 5 bpm) ⁷. The takeaway is the same across all of them: if you have persistent racing or pounding at rest, call the prescriber — don’t make a medication change off a web page.

Could your blood pressure actually go up? For an individual, sure — readings can rise for all sorts of reasons, from a bad measurement to caffeine to stress to something unrelated. The move is the same: re-check it correctly, look at the trend over several days, and flag a persistent or big increase to your clinician rather than blaming or clearing the medicine on one number.

What blood pressure reading is too low on a GLP-1?

Under about 90/60 mmHg is commonly called “low,” but one lower-than-normal reading usually isn’t cause for alarm if you feel well. Symptoms — dizziness, confusion, fainting, nausea, blurred vision, unusual fatigue, or a racing heart — are what turn a low or fast-falling number into something to act on.

There’s no magic cutoff that fits everyone. The American Heart Association commonly describes hypotension as below 90/60, but it also notes a low reading is usually not harmful unless you have symptoms or another problem ¹⁰.

Real triggers to contact your clinician:

• ✓Readings well below your usual range, more than once
• ✓Dizziness or near-fainting that keeps happening, especially on standing
• ✓Vomiting or diarrhea you can't get on top of, or trouble keeping fluids down
• ✓A recent dose increase plus new symptoms
• ✓A blood pressure medicine (especially more than one) plus a clear downward trend

Your clinician may have given you a personal target. If they did, that number beats any general range on the internet — including ours.

How should you check and log your blood pressure on a GLP-1?

Use a validated upper-arm cuff and measure the same way each time, because sloppy technique can hide a real change of just a few mmHg. The American Heart Association’s log suggests two readings a minute apart, twice a day, for at least three days — ideally seven — before an appointment.

The blood pressure effect of a GLP-1 is small enough that bad technique can erase it (or fake it). So a few minutes of doing it right is worth more than a fancy device ¹².

Also jot down: your pulse, any symptoms, whether they came on when you stood, your GLP-1 dose and when you last increased it, your blood pressure medicine names and timing, whether you use a diuretic, and any vomiting, diarrhea, or low food/fluid intake.

And here’s the mindset shift: the pattern beats the lowest number. One reading can just be noise. A week of paired readings, lined up with your symptoms and dose, gives your clinician something they can actually use.

Build your free 7-day GLP-1 blood pressure log

We built a simple log where you enter your morning and evening readings, your pulse, any symptoms, and your dose changes — and it turns them into a clean, printable summary you can bring (or send) to your clinician. It shows your trend, flags patterns worth a conversation, and gives you a list of questions to ask. It does not diagnose you, and it will never tell you to stop, lower, or delay a prescription.

Free, print-ready format — no sign-up required. Use the steps above to fill it in and bring it to your clinician.

Is a GLP-1 a substitute for blood pressure medication?

No. High blood pressure isn’t an approved use for Wegovy, Zepbound, or Foundayo, and the reductions — while real — are smaller than what dedicated blood pressure drugs deliver. Any change to your blood pressure medicine should follow real readings, your symptoms, and your clinician’s judgment — not a lower number on a good day.

Standard blood pressure medicines — the ones whose whole job is controlling it — lower the top number more. One large 2025 review found a typical single blood pressure drug lowers systolic pressure by roughly 8 to 9 mmHg ¹³. GLP-1 medicines average around 3 mmHg across the class, a bit more (around 5 mmHg) for the tirzepatide-type dual agonists ¹³. Those figures are context, not a fair head-to-head — the studies used different people and starting pressures — but they make the point: a GLP-1 can help your blood pressure, but it’s not built to replace a medicine designed to control it.

If your readings improve a lot, that’s fantastic — and it may open the door to your prescriber reducing a blood pressure medicine, under supervision. If your real interest is picking a medication with your blood pressure in mind, see: Best GLP-1 for High Blood Pressure.

Do the blood pressure benefits last if you stop the medicine?

Maybe not. In a follow-up of the STEP 1 semaglutide trial, average top- and bottom-number pressure drifted back up after people stopped the medicine and lifestyle program, returning to about their starting levels by around week 120. That was an exploratory look at 327 people — it doesn’t predict any one person’s exact path.

GLP-1s work while you take them. In that semaglutide follow-up, people regained roughly two-thirds of their earlier weight loss over the following year, and blood pressure returned toward baseline at the group level ⁹. So a lower reading reached on treatment shouldn’t be assumed permanent — and that’s about semaglutide in one study, not a universal rule for every GLP-1.

If you’re stopping or switching, keep an eye on your blood pressure trend and your weight, and make sure there’s a plan for your blood pressure medicine so nothing gets missed in the handoff.

Who needs closer blood pressure follow-up?

Closer monitoring is especially worth it for people on blood pressure medicine (particularly more than one, or a diuretic), people starting with low-normal pressure, people dealing with vomiting or diarrhea, and anyone with a history of dizziness or fainting. The FDA labels specifically flag blood pressure medicine use and fluid loss as situations tied to low-BP events.

Quick self-check — you’re in the “measure more carefully” group if any of these fit ¹ ²:

• ▶You take a blood pressure medicine — especially two or more, or a diuretic
• ▶Your usual blood pressure runs low-normal
• ▶You've fainted or felt faint before, or get dizzy on standing
• ▶You're prone to dehydration or are having ongoing stomach upset
• ▶You're older or at risk of falls

A few situations sit outside what a general guide should handle — pregnancy, kids, advanced kidney disease, complex heart disease, and hard-to-control blood pressure all need care built around your specific situation. If that’s you, treat this page as background, not a plan.

What should you ask your prescriber before starting or increasing a GLP-1?

The best questions turn a general warning into a plan built for you: what blood pressure range is concerning for you, how long to log readings, who adjusts your BP medicine if it falls, and what to do during vomiting or diarrhea. Bring every clinician the same readings and medication list.

Copy this, fill in your answers, and you’ve done more prep than most people ever do:

How did The RX Index verify this page?

We built this page from current FDA prescribing information, primary trial publications, prespecified substudies, post hoc analyses of randomized trials, systematic reviews, and American Heart Association measurement guidance. We did not use provider marketing pages, affiliate payouts, forum stories, or customer testimonials to establish any medical fact.

What we actually verified (July 2026):

• ✓Wegovy (semaglutide) prescribing information, revised Feb 2026 — low-BP, syncope, and heart-rate numbers
• ✓Zepbound (tirzepatide) prescribing information, revised Jan 2026 — low-BP, blood-pressure-medicine subgroup, and heart-rate numbers
• ✓Semaglutide blood pressure analysis, European Heart Journal, 2024
• ✓SELECT cardiovascular trial, NEJM, 2023
• ✓SURMOUNT-1 24-hour blood pressure substudy, Hypertension, 2024
• ✓SURPASS 1-5 blood pressure analysis
• ✓Foundayo (orforglipron) FDA approval and clinical data, Eli Lilly, 2026
• ✓STEP 1 off-treatment follow-up (blood pressure and weight after stopping)
• ✓American Heart Association guidance on low blood pressure, emergency readings, and home measurement

What we did not do: we didn’t enroll with a provider, test a medicine, claim medical review, use a customer story as proof, rank drugs from unlike trials, or transfer FDA-approved trial results to compounded versions.

Written and fact-checked by the The RX Index Editorial Team. Independent guidance for choosing your GLP-1 path. See our editorial standards.

What should you do next?

Your next step depends on why you’re here. Symptoms or unusually low readings call for a proper log and a clinician conversation. Early research calls for understanding the effect first. Choosing a provider calls for a personalized match — not a one-size-fits-all pick.

Frequently asked questions about GLP-1 blood pressure effects